Mode
Text Size
Log in / Sign up

Minocycline-based regimens are noninferior to bismuth quadruple therapy for refractory H. pylori eradicationNew minocycline treatment shows promise for stubborn stomach infections

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider minocycline-based regimens as a noninferior alternative to tetracycline-based therapy for refractory H. pylori.

This randomized controlled trial evaluated the efficacy of three different minocycline-containing regimens compared to a classical tetracycline-based bismuth quadruple therapy (BQT) in 480 participants with refractory H. pylori infection and multiple treatment failures. The BQT included vonoprazan 20 mg b.i.d., bismuth 220 mg b.i.d., tetracycline 400 mg q.i.d., and metronidazole 500 mg q.i.d.

In the intention-to-treat analysis, the eradication rates were 90.0% for BQT, 92.5% for VBMnM (t.i.d.), 90.8% for VBMnM (b.i.d. mino/q.i.d. met), and 91.7% for VBMnM (b.i.d. mino/t.i.d. met). The study reported no statistically significant differences between the groups, with a p-value < 0.025 for the noninferiority of minocycline-based regimens. Modified intention-to-treat analysis showed even higher eradication rates, ranging from 96.5% to 97.4% across all groups.

Regarding safety, the VBMnM group (50 mg b.i.d. minocycline and 400 mg t.i.d. metronidazole) reported the lowest overall incidence of adverse events. The study noted that metronidazole resistance did not affect the efficacy of the treatments. These minocycline-based regimens may serve as a practical substitute for rescue treatment when tetracycline is unavailable.

How this fits prior evidence

How this fits prior evidence: This study addresses a gap in rescue treatment options for H. pylori. While a previous finding noted that Lactobacillus-supplemented therapy increases Helicobacter pylori eradication success by 10% and reduces adverse events, this study provides a specific alternative for patients with multiple treatment failures where tetracycline is unavailable. It confirms the utility of minocycline in H. pylori treatment, similar to its role in other conditions.

Living with a stubborn stomach infection caused by H. pylori can be incredibly frustrating. For many people, the bacteria are so hardy that standard treatments fail multiple times, leaving the infection deep in the stomach. This makes finding a reliable backup plan essential for those who cannot clear the infection with first-line drugs.

A study of 480 people with these difficult cases compared three different minocycline-based plans against a standard tetracycline-based treatment. The results were encouraging. All three minocycline groups showed eradication rates between 90.8% and 92.5%. These results were not significantly different from the standard treatment, which had a 90.0% success rate.

One specific minocycline mix was noted for being particularly well-tolerated by patients. While the study is still early, these findings suggest that minocycline is a practical and effective substitute when the usual medications are unavailable or do not work. Talk to your doctor if you have a persistent infection to see if these options fit your needs.

What this means for you:
Minocycline-based treatments are a reliable alternative for clearing stubborn H. pylori infections.

Common questions

Is minocycline effective for stubborn H. pylori infections?

Yes, the study showed that three different minocycline-based regimens were not significantly different from the standard tetracycline-based treatment. These regimens achieved eradication rates between 90.8% and 92.5%, while the standard treatment had a 90.0% success rate. This makes minocycline a practical substitute when standard drugs are unavailable.

Are there side effects to the minocycline treatment?

The study tracked how well patients tolerated the medicine. One specific minocycline combination (50 mg b.i.d. minocycline and 400 mg t.i.d. metronidazole) was found to have the lowest overall incidence of adverse events among the groups tested.

Who is this treatment for?

This treatment was tested in 480 participants who had refractory H. pylori infections. These are cases where the infection was particularly hard to treat and the patients had already experienced multiple treatment failures.

Study Details

Study typeRct
Sample sizen = 480
EvidenceLevel 2
PublishedOct 2026
View Original Abstract ↓
BACKGROUND AND AIM: Minocycline-containing bismuth quadruple therapy may provide a practical option for Helicobacter pylori (H. pylori) rescue treatment when tetracycline is unavailable, yet the optimal dosing remains unclear. We aimed to compare the efficacy and safety of different doses of minocycline-containing regimens with classical tetracycline-based bismuth quadruple therapy. METHODS: Refractory H. pylori-infected participants with multiple treatment-failure were randomly (1:1:1:1) allocated to receive 14-day therapy with vonoprazan 20 mg b.i.d, bismuth 220 mg b.i.d, plus tetracycline 400 mg q.i.d and metronidazole 500 mg q.i.d (BQT), or minocycline 50 mg t.i.d and metronidazole 400 mg t.i.d (VBMnM), or minocycline 50 mg b.i.d and metronidazole 400 mg q.i.d (VBMnM), or minocycline 50 mg b.i.d and metronidazole 400 mg t.i.d (VBMnM). Primary outcome was H. pylori eradication rate evaluated by C-urea breath test at least 6 weeks after the end of treatment. RESULTS: Totally, 480 participants were randomized. Eradication rates of BQT, VBMnM, VBMnM, and VBMnM were 90.0%, 92.5%, 90.8%, and 91.7% by intention-to-treat analysis; 97.3%, 97.4%, 97.3%, and 96.5% by modified intention-to-treat analysis; 98.2%, 97.4%, 97.2%, and 96.4% by per-protocol analysis. There were no statistically significant differences in eradication rates among the regimens, and noninferiority of minocycline-based regimens was confirmed (p < 0.025). Metronidazole resistance did not affect the efficacy. VBMnM group achieved the lowest overall incidence of adverse events. CONCLUSIONS: Low-dose minocycline-containing quadruple therapy provided similar eradication rates, adherence, and lower adverse event rates compared with classical bismuth quadruple therapy, and may serve as a practical substitute strategy for H. pylori rescue treatment when tetracycline access is limited. TRIAL REGISTRATION: ClinicalTrials.gov: NCT06561711.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.